An explanation for this difference in observations may be that Hansen et al. used monoclonal IgA subclasses, which are often myeloma-derived and are characterized by aberrant glycosylation profiles, while Steffen et al. used IgA antibodies isolated from healthy human serum [40,42,68]. The gene discussed is CD79A; the disease is plasma cell myeloma.